CA2478082A1 - Utilisations d'anticorps 8h9 monoclonaux - Google Patents

Utilisations d'anticorps 8h9 monoclonaux Download PDF

Info

Publication number
CA2478082A1
CA2478082A1 CA002478082A CA2478082A CA2478082A1 CA 2478082 A1 CA2478082 A1 CA 2478082A1 CA 002478082 A CA002478082 A CA 002478082A CA 2478082 A CA2478082 A CA 2478082A CA 2478082 A1 CA2478082 A1 CA 2478082A1
Authority
CA
Canada
Prior art keywords
antibody
tumor
cells
cell
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002478082A
Other languages
English (en)
Other versions
CA2478082C (fr
Inventor
Nai-Kong V. Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/097,558 external-priority patent/US7737258B2/en
Priority claimed from US10/273,762 external-priority patent/US7666424B2/en
Application filed by Individual filed Critical Individual
Publication of CA2478082A1 publication Critical patent/CA2478082A1/fr
Application granted granted Critical
Publication of CA2478082C publication Critical patent/CA2478082C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
CA2478082A 2002-03-08 2003-03-06 Utilisations d'anticorps 8h9 monoclonaux Expired - Lifetime CA2478082C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/097,558 2002-03-08
US10/097,558 US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
PCT/US2002/033331 WO2003033670A2 (fr) 2001-10-17 2002-10-17 Procede de preparation d'anticorps monocatenaires
US10/273,762 2002-10-17
US10/273,762 US7666424B2 (en) 2001-10-17 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
USPCT/US02/33331 2002-10-17
PCT/US2003/007004 WO2003075846A2 (fr) 2002-03-08 2003-03-06 Utilisations d'anticorps 8h9 monoclonaux

Publications (2)

Publication Number Publication Date
CA2478082A1 true CA2478082A1 (fr) 2003-09-18
CA2478082C CA2478082C (fr) 2016-02-02

Family

ID=27808456

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2478082A Expired - Lifetime CA2478082C (fr) 2002-03-08 2003-03-06 Utilisations d'anticorps 8h9 monoclonaux

Country Status (3)

Country Link
AU (1) AU2003220079A1 (fr)
CA (1) CA2478082C (fr)
WO (1) WO2003075846A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
CA2508519A1 (fr) * 2002-12-02 2004-06-17 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
JP5597793B2 (ja) 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
KR20100014527A (ko) * 2007-03-22 2010-02-10 슬로안-케테링인스티튜트퍼캔서리서치 단일클론항체 8ｈ9의 용도
CA2826942C (fr) * 2011-02-11 2021-08-03 Memorial Sloan-Kettering Cancer Center Proteines de liaison a l'antigene specifiques d'un peptide a restriction hla
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
WO2016106004A1 (fr) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Nouveaux composés de liaison anti-b7h3 et leurs utilisations
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2021037319A1 (fr) 2019-08-30 2021-03-04 Y-Mabs Therapeutics, Inc. Évaluation immunohistochimique de l'expression de b7-h3
WO2021127217A1 (fr) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
CA3184366A1 (fr) 2020-06-29 2022-01-06 Darby Rye Schmidt Virus modifies pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
WO2022212784A1 (fr) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
EP4363059A1 (fr) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer

Also Published As

Publication number Publication date
AU2003220079A1 (en) 2003-09-22
WO2003075846A3 (fr) 2005-08-11
CA2478082C (fr) 2016-02-02
WO2003075846A2 (fr) 2003-09-18
AU2003220079A8 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
US9938351B2 (en) Uses of monoclonal antibody 8H9
US9062110B2 (en) Uses of monoclonial antibody 8H9
US7737258B2 (en) Uses of monoclonal antibody 8H9
US20020102264A1 (en) Uses of monoclonal antibody 8H9
CA2478082C (fr) Utilisations d'anticorps 8h9 monoclonaux
CA2423843A1 (fr) Utilisations d'anticorps monoclonal 8h9
US7740845B2 (en) Uses of monoclonal antibody 8H9
Mehren et al. Monoclonal antibody therapy for cancer
ES2350477T5 (es) Internalización de anticuerpos anti-CD74 y métodos de uso
US8148154B2 (en) Method for preparation of single chain antibodies
Lutterbuese et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
JP4790831B2 (ja) 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法
US20040115205A1 (en) Use of antibodies against the MUC18 antigen
US20030147809A1 (en) Antibodies against the MUC18 antigen
US20030152514A1 (en) Methods for using anti-MUC18 antibodies
HUE031151T2 (en) Pharmaceutical compositions resistant to soluble CEA
MXPA05007245A (es) Inmunoterapia de malignidades de celula b y enfermedad autoinmune utilizando anticuerpos no conjugados y anticuerpos conjugados combinaciones de anticuerpos y proteinas de fusion.
Cheung et al. Methods of preparing and using single chain anti-tumor antibodies
Cheung et al. Method for preparation of single chain antibodies
Goel et al. Antibody constructs for radioimmunodiagnosis and treatment of human pancreatic cancer
Krauss et al. Application of recombinant antibodies in cancer patients
CN117964761A (zh) 抗trem2抗体及其用途
Colnaghi Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150716

FZDC Discontinued application reinstated

Effective date: 20151110

MKEX Expiry

Effective date: 20230306